The damage has certainly been widespread. The tech-heavy Nasdaq 100 is in correction territory, down more than 10% off highs. The S&P 500 isn't as bad, down only 3-5% off highs. But within the index itself, more than 50% of its members are down more than 20%. That's bear-market territory.
His firm sees all this as a result of concern around interest rates, the geopolitical picture in both Europe and the Middle East, and concerns around the sustainability of AI spending to garner returns.
As always, the answer's never straightforward. You have to balance the bullish case and the bear case, and then pick a side.
Let's starts with the bear case. Runaway inflation is one point. If the Strait of Hormuz remains closed, the Fed will be forced to continue hiking interest rates. To the extent that AI spending has potentially peaked, that will have to drive further multiple and earnings compression.
From a bullish point of view, is the earnings backdrop in the AI ecosystem sustainable? From his team's perspective, it is. Other sectors are starting to participate, such as healthcare.
More importantly, as stock-pickers, are there opportunities to be found out there? Stocks trading at attractive valuations relative to growth prospects? In June/July of this year, the answer was firmly no. Increasingly, it's becoming yes. His firm is excited about the opportunities.
(Note the shortish timeframe.) Financials don't perform well when there are a lot of economic and geopolitical uncertainties. At the time, no war in the Middle East was contemplated, nor did inflation appear to be going as high as it has.
Still owns, still likes its turnaround story, management decisions, and valuation.
Note that biotech is very risky and very volatile, so tread carefully. In general, you want class-leading drugs, optionality for bigger markets or "other indications", reasonable valuation compared to potential sales.
Its drug treats Multiple Sclerosis, and uses new research to target the appropriate cells (not T cells as before). MS affects ~2.9M people globally. Approaching $1B in revenue. Catalyst is in-home use of the MS drug. No dividend.
Helps biopharma companies conduct clinical research, phase 1-4 trials. All that used to be done in-house, now much is outsourced. MEDP skews toward smaller and emerging biotech firms, which often don't have resources to do trials in-house. Valuation's a bit high, but justified. No dividend.
(Analysts’ price target is $674.75)The economy has different layers of reflexivity -- one factor influences another, which then influences the first. If you go back 10-20 years, it was really a consumer-led economy. If the consumer is doing well, they spend $$, that feeds the economy, which then eventually feeds equities.
Over the last 3-5 years, it's been industrial investment driving the global economy. Not the consumer. Some has been AI, some has been onshoring. Ultimately, the consumer is part of the industrial economy. If the consumer weakens, that may lead to less domestic investment.
A colleague in his office reminded him of the "Henry Ford effect". Ford said that he pays his employees well because, ultimately, they're the ones who buy the cars.
Not performing particularly well, but not because of the company itself. Uncertainty around autonomous vehicles. Industrial sector's been under pressure, and investors just sell the group.
UBER's fundamentals are good, autonomous industry will be a benefit, industrial malaise will dissipate. True value is its logistical algorithms.
Growth rate has decelerated substantially. Streaming wars mean it has to continuously invest in content, so profitability is much lower. May not have growth as before, but has longevity.
Trades 17x PE, low-moderate growth, moderately capital-intensive. Will eventually get too cheap relative to its value. Compelling in range of low-mid $40s.